magnesium carbonate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4288	546-93-0

Description:

Molecule	Description
Synonyms: magnesium carbonate carbonic acid magnesium salt	Molecular weight: 84.31 Formula: CMgO3 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

magnesium carbonate
carbonic acid magnesium salt

Molecular weight: 84.31
Formula: CMgO3
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
7	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Oct. 2, 1990	FDA	UNITED GUARDIAN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Vaginal flatulence	62.79	14.43	19	5006	3274	63480723
Proctitis	57.23	14.43	20	5005	5421	63478576
Radiculopathy	48.30	14.43	20	5005	8591	63475406
Female genital tract fistula	47.34	14.43	19	5006	7540	63476457
Vaginal discharge	43.74	14.43	19	5006	9179	63474818
Chronic sinusitis	37.68	14.43	19	5006	12824	63471173
Colitis	35.57	14.43	30	4995	48498	63435499
Paraesthesia oral	33.05	14.43	20	5005	19236	63464761
Frequent bowel movements	32.19	14.43	21	5004	23001	63460996
Macular degeneration	31.10	14.43	21	5004	24355	63459642
Oral candidiasis	29.95	14.43	20	5005	22778	63461219
Colitis ulcerative	29.81	14.43	21	5004	26070	63457927
Procedural pain	28.52	14.43	19	5006	21550	63462447
Hyponatraemia	24.84	14.43	37	4988	111863	63372134
Morbid thoughts	22.86	14.43	6	5019	617	63483380
Epilepsy	22.48	14.43	18	5007	27047	63456950
Coma scale abnormal	22.41	14.43	10	5015	5143	63478854
Rectal haemorrhage	21.85	14.43	23	5002	49007	63434990
Periventricular leukomalacia	19.83	14.43	4	5021	127	63483870
Anaemia	19.36	14.43	59	4966	293371	63190626
Dyspepsia	17.46	14.43	30	4995	102166	63381831
Haematochezia	16.88	14.43	21	5004	53523	63430474
Agitation	16.58	14.43	22	5003	59735	63424262
Jaundice neonatal	16.20	14.43	5	5020	920	63483077
Maternal drugs affecting foetus	16.09	14.43	8	5017	5234	63478763
Abdominal pain	15.74	14.43	55	4970	293401	63190596
Confusional state	15.08	14.43	47	4978	236333	63247664
Melaena	14.89	14.43	15	5010	30350	63453647
Hypertriglyceridaemia	14.76	14.43	8	5017	6251	63477746
Acute kidney injury	14.67	14.43	50	4975	263365	63220632

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood phosphorus increased	72.15	20.48	27	3176	7694	34946034
Appendicolith	69.31	20.48	27	3176	8574	34945154
Appendicitis	61.28	20.48	29	3174	14778	34938950
Myasthenia gravis	49.66	20.48	20	3183	6920	34946808
Cardiogenic shock	47.85	20.48	30	3173	26588	34927140
Ventricular fibrillation	46.69	20.48	28	3175	22926	34930802
Blood uric acid increased	46.52	20.48	21	3182	9603	34944125
Mesothelioma	45.08	20.48	10	3193	435	34953293
Dry mouth	44.42	20.48	30	3173	30135	34923593
Stress	39.55	20.48	28	3175	30319	34923409
Abdominal distension	38.07	20.48	36	3167	58456	34895272
Hyponatraemia	32.63	20.48	39	3164	82652	34871076
Blood cholesterol increased	31.59	20.48	21	3182	20522	34933206
Multiple organ dysfunction syndrome	28.39	20.48	35	3168	76531	34877197
Vomiting	27.46	20.48	66	3137	247555	34706173
Ascites	27.16	20.48	27	3176	46544	34907184
Hyperphosphataemia	25.70	20.48	11	3192	4426	34949302
Incorrect route of product administration	24.83	20.48	16	3187	14829	34938899
General physical health deterioration	24.68	20.48	43	3160	128226	34825502
Analgesic therapy	23.46	20.48	7	3196	991	34952737
Sleep disorder therapy	23.29	20.48	7	3196	1016	34952712
Abdominal pain	23.02	20.48	48	3155	163570	34790158
Violence-related symptom	22.89	20.48	6	3197	530	34953198
Drug therapy	22.54	20.48	7	3196	1134	34952594
Somnolence	21.04	20.48	37	3166	111079	34842649
Iron deficiency	20.61	20.48	10	3193	5371	34948357

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	71.88	14.95	27	6624	8524	79729213
Blood phosphorus increased	70.35	14.95	28	6623	10319	79727418
Vaginal flatulence	61.95	14.95	18	6633	2557	79735180
Appendicitis	57.31	14.95	30	6621	20764	79716973
Proctitis	49.34	14.95	19	6632	6413	79731324
Hyponatraemia	49.06	14.95	67	6584	177781	79559956
Female genital tract fistula	47.09	14.95	18	6633	5957	79731780
Blood uric acid increased	44.77	14.95	22	6629	13338	79724399
Myasthenia gravis	43.66	14.95	20	6631	10379	79727358
Radiculopathy	43.53	14.95	19	6632	8805	79728932
Vaginal discharge	43.21	14.95	18	6633	7445	79730292
Ventricular fibrillation	42.97	14.95	29	6622	31897	79705840
Macular degeneration	36.06	14.95	18	6633	11278	79726459
Cardiogenic shock	35.90	14.95	29	6622	41885	79695852
Abdominal distension	32.85	14.95	45	6606	119605	79618132
Dry mouth	31.89	14.95	38	6613	87981	79649756
Violence-related symptom	31.08	14.95	8	6643	723	79737014
Chronic sinusitis	30.86	14.95	17	6634	13009	79724728
Abdominal pain	28.48	14.95	84	6567	389485	79348252
Incorrect route of product administration	27.47	14.95	23	6628	34906	79702831
Oral candidiasis	26.43	14.95	21	6630	29607	79708130
Paraesthesia oral	26.13	14.95	18	6633	20453	79717284
Colitis	25.49	14.95	31	6620	73276	79664461
Stress	25.01	14.95	32	6619	79580	79658157
Frequent bowel movements	24.37	14.95	20	6631	29519	79708218
Procedural pain	24.18	14.95	18	6633	23066	79714671
Analgesic therapy	24.04	14.95	7	6644	1002	79736735
Sleep disorder therapy	23.93	14.95	7	6644	1017	79736720
Colitis ulcerative	23.52	14.95	21	6630	34721	79703016
Hyperphosphataemia	22.86	14.95	11	6640	6365	79731372
Drug therapy	22.83	14.95	7	6644	1194	79736543
General physical health deterioration	21.68	14.95	61	6590	275177	79462560
Morbid thoughts	21.05	14.95	6	6645	796	79736941
Mesothelioma	20.55	14.95	5	6646	359	79737378
Multiple organ dysfunction syndrome	20.09	14.95	36	6615	120210	79617527
Vomiting	19.58	14.95	108	6543	665720	79072017
Blood cholesterol increased	19.31	14.95	29	6622	83691	79654046
Somnolence	18.85	14.95	53	6598	238928	79498809
Glomerular filtration rate	18.83	14.95	4	6647	156	79737581
Epilepsy	18.82	14.95	20	6631	40840	79696897
Ascites	18.62	14.95	27	6624	75535	79662202
Iron deficiency	17.57	14.95	11	6640	10643	79727094
Dyspepsia	17.47	14.95	32	6619	108655	79629082
Myeloid maturation arrest	16.99	14.95	3	6648	43	79737694
Coma scale abnormal	16.99	14.95	10	6641	8668	79729069

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A02AA01	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS ANTACIDS Magnesium compounds
ATC	A06AD01	ALIMENTARY TRACT AND METABOLISM DRUGS FOR CONSTIPATION DRUGS FOR CONSTIPATION Osmotically acting laxatives
MeSH PA	D057886	Bleaching Agents
MeSH PA	D058427	Hygroscopic Agents
MeSH PA	D016877	Oxidants
CHEBI has role	CHEBI:33287	fertilizers
CHEBI has role	CHEBI:65265	antacids

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Peptic ulcer	indication	13200003	DOID:750
Constipation	indication	14760008	DOID:2089
Heartburn	indication	16331000
Indigestion	indication	162031009
Hypomagnesemia	indication	190855004
Gastroesophageal reflux disease	indication	235595009	DOID:8534
Incomplete passage of stool	indication	249515001
Struvite Renal Calculi	indication
Calcium Phosphate Renal Calculi	indication
Hiatal Hernia with Reflux Esophagitis	indication
Gastric Hypersecretory Conditions	indication
Hypocalcemia	off-label use	5291005
Multiple endocrine adenomas	off-label use	60549007
Osteoporosis	off-label use	64859006	DOID:11476
Postmenopausal osteoporosis	off-label use	102447009
Systemic mast cell disease	off-label use	397016004	DOID:349
Stress-Related GI Mucosal Bleeding Prevention	off-label use
Renal Osteodystrophy with Hyperphosphatemia	off-label use
Hypophosphatemia	contraindication	4996001
Suicidal thoughts	contraindication	6471006
Alcoholism	contraindication	7200002
Hyperammonemia	contraindication	9360008
Hepatic encephalopathy	contraindication	13920009	DOID:13413
Sarcoidosis	contraindication	31541009	DOID:11335
Dehydration	contraindication	34095006
Depressive disorder	contraindication	35489007
Fecal impaction	contraindication	44635007
Hepatic failure	contraindication	59927004
Diarrhea	contraindication	62315008
Poisoning by phenobarbital	contraindication	64921004
Substance abuse	contraindication	66214007
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Hemorrhoids	contraindication	70153002	DOID:9746
Hypercalciuria	contraindication	71938000
Hepatic coma	contraindication	72836002	DOID:12550
Sleep apnea	contraindication	73430006	DOID:0050847
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Gastrointestinal obstruction	contraindication	126765001
Osteolysis	contraindication	203522001
Disease of liver	contraindication	235856003	DOID:409
Chronic diarrhea	contraindication	236071009
Aluminum intoxication	contraindication	236546003
Dyspnea	contraindication	267036007
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Breastfeeding (mother)	contraindication	413712001
Porphyria	contraindication	418470004

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4017631	VUID
N0000146011	NUI
D01446	KEGG_DRUG
4017631	VANDF
C0065517	UMLSCUI
CHEBI:31793	CHEBI
CHEMBL1200736	ChEMBL_ID
DB09481	DRUGBANK_ID
C005479	MESH_SUPPLEMENTAL_RECORD_UI
0E53J927NA	UNII
11029	PUBCHEM_CID
29155	RXNORM
29720	MMSL
5008	MMSL
5560	MMSL
d03588	MMSL
000785	NDDF
001120	NDDF
007230	NDDF
387401007	SNOMEDCT_US
7168001	SNOMEDCT_US
17968-26-2	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
GAVISCON	HUMAN OTC DRUG LABEL	2	0135-0094	LIQUID	358 mg	ORAL	OTC monograph final	13 sections
GAVISCON	HUMAN OTC DRUG LABEL	2	0135-0095	LIQUID	237.50 mg	ORAL	OTC monograph final	13 sections
GavisconExtra Strength	HUMAN OTC DRUG LABEL	2	0135-0098	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	15 sections
GavisconExtra Strength	HUMAN OTC DRUG LABEL	2	0135-0098	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	15 sections
GavisconExtra Strength	HUMAN OTC DRUG LABEL	2	0135-0430	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	15 sections
GavisconExtra Strength	HUMAN OTC DRUG LABEL	2	0135-0430	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	15 sections
GAVISCON	HUMAN OTC DRUG LABEL	2	0135-0574	LIQUID	237.50 mg	ORAL	OTC monograph final	13 sections
Renacidin	HUMAN PRESCRIPTION DRUG LABEL	3	0327-0012	SOLUTION	3.27 g	IRRIGATION	NDA	14 sections
FAST ACTING Heartburn Relief	HUMAN OTC DRUG LABEL	2	0363-1155	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
FAST ACTING Heartburn Relief	HUMAN OTC DRUG LABEL	2	0363-1155	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
Walgreens Fast Acting Heartburn Relief Extra Strength	HUMAN OTC DRUG LABEL	2	0363-7630	LIQUID	237.50 mg	ORAL	OTC monograph final	13 sections
Walgreens Fast Acting Heartburn Relief Extra Strength	HUMAN OTC DRUG LABEL	2	0363-7630	LIQUID	237.50 mg	ORAL	OTC monograph final	13 sections
Humco Dewees Carminative	HUMAN OTC DRUG LABEL	1	0395-0713	SUSPENSION	50 mg	ORAL	OTC monograph final	12 sections
Humco Dewees Carminative	HUMAN OTC DRUG LABEL	1	0395-0713	SUSPENSION	50 mg	ORAL	OTC monograph final	12 sections
Acid Gone AntacidExtra Strength	HUMAN OTC DRUG LABEL	2	0904-5365	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
Acid Gone AntacidExtra Strength	HUMAN OTC DRUG LABEL	2	0904-5365	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
ACID GONE ANTACID	HUMAN OTC DRUG LABEL	2	0904-7727	LIQUID	358 mg	ORAL	OTC monograph final	10 sections
Extra StrengthAntacid	HUMAN OTC DRUG LABEL	2	11673-814	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
Extra StrengthAntacid	HUMAN OTC DRUG LABEL	2	11673-814	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
Rite Aid Extra Strength	HUMAN OTC DRUG LABEL	2	11822-1050	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
Rite Aid Extra Strength	HUMAN OTC DRUG LABEL	2	11822-1051	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
Rite Aid Extra Strength	HUMAN OTC DRUG LABEL	2	11822-1051	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
EXTRA STRENGTH HEARTBURN RELIEF ANTACID	HUMAN OTC DRUG LABEL	2	11822-6862	SUSPENSION	237.50 mg	ORAL	OTC monograph final	10 sections
Kroger Extra Strength	HUMAN OTC DRUG LABEL	2	30142-610	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
Kroger Extra Strength	HUMAN OTC DRUG LABEL	2	30142-610	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
Kroger Extra Strength	HUMAN OTC DRUG LABEL	2	30142-610	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
HEB Extra StrengthOriginal Flavor	HUMAN OTC DRUG LABEL	2	37808-505	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
HEB Extra StrengthOriginal Flavor	HUMAN OTC DRUG LABEL	2	37808-505	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
HEB Extra StrengthCherry Flavor	HUMAN OTC DRUG LABEL	2	37808-510	TABLET, CHEWABLE	105 mg	ORAL	OTC monograph final	12 sections
HEB Extra StrengthCool Mint	HUMAN OTC DRUG LABEL	2	37808-632	LIQUID	237.50 mg	ORAL	OTC monograph final	13 sections